Source: BUSINESS WIRE

Press Release: BioAlliance Pharma : BioAlliance Pharma: Approval of Onxeo's admission to secondary listing and trading on NASDAQ OMX Copenhagen

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE)--Regulatory News: In continuation of their joint company announcement of July 23, 2014, BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative company specialized in the development of drugs in orphan oncology diseases newly renamed Onxeo, and Topotarget A/S (NASDAQ OMX Copenhagen - TOPO), today announce that NASDAQ OMX Copenhagen has approved Onxeo's admission to secondary trading and official listing on NASDAQ OMX Copenhagen to be

Read full article »
Est. Annual Revenue
$5.0-25M
Agree?
Est. Employees
1-25
Agree?
CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100



BioAlliance Pharma is a Private company. BioAlliance Pharma has a revenue of $10M, and 10 employees. BioAlliance Pharma has 1 followers on Owler.